my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
02-01-2012: The Drugs for Neglected Diseases initiative (DNDi) and Abbott have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness. Through this collaboration, DNDi and Abbott scientists will focus initial efforts on discovering and advancing novel antimicrobial agents with activity against these neglected diseases.
Since 2009, Abbott has provided compounds for DNDi to screen for activity against neglected diseases. This new agreement expands this relationship, and provides DNDi access to selected classes of molecules and accompanying data generated by Abbott that are crucial for the development of effective and accessible new treatments for neglected diseases.
Equitable access to treatments for neglected diseases in all endemic countries, not only least-developed countries, is at the core of this agreement, and DNDi has committed to ensuring the lowest sustainable pricing for any products developed and distributed as a result of the agreement. Intellectual property (IP) related to this agreement, existing relevant Abbott IP and new IP generated by this collaboration will be subject to a principle of non-exclusive licensing to address neglected diseases in endemic countries. Under the agreement, Abbott has the right of first negotiation to become DNDi's development and distribution partner. DNDi is free to engage other partners if Abbott chooses not to serve as a development and distribution partner.
The agreement, in short implies:
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Abbott and Action Pharma A/S announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma.AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in patients at increased risk and has further potential in ... more
Abbott Announces Collaboration with Syngene to Open Nutrition R&D Center
Abbott announced plans to establish its first nutrition research and development center in the country in collaboration with Syngene. The Abbott Nutrition R&D Center in India will focus on the development of science-based, affordable nutrition products for the country and enable the expansi ... more
Abbott's HUMIRA Approved in Europe for Treatment of Ulcerative Colitis
Abbott announced that the European Commission has approved HUMIRA®(adalimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response to conventional therapy. With this approval, HUMIRA becomes the first and only self ... more
Abbott de Mexico, S.A. de C.V.
We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Our comp ... more
To meet the ever growing needs of modern medicine and combat emerging new diseases, there is a constant demand for improved diagnostic methods, therapeutic approaches and technologies. As a leading manufacturer of health care products, it is Abbott's goal to meet these needs worldwide. In G ... more
To meet the ever growing needs of modern medicine and combat emerging new diseases, there is a constant demand for improved diagnostic methods, therapeutic approaches and technologies. As a leading manufacturer of health care products, it is Abbott's goal to meet these needs worldwide. In G ... more
DNDi and Abbott Expand Partnership to Boost Innovation for Neglected Tropical Diseases
The Drugs for Neglected Diseases initiative (DNDi) and Abbott have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leis ... more
New Consortium to Develop Drugs for Neglected Tropical Diseases
A new consortium has been formed to boost drug development for the treatment of two deadly diseases, African sleeping sickness and Leishmaniasis. A total budget of nearly 3.6 million euros has been allocated over the next 4 years, to develop effective drugs for these diseases. The consortiu ... more
Drugs for Neglected Diseases initiative (DNDi)
In 2003, seven organisations from around the world joined forces to establish DNDi: five public sector institutions the Oswaldo Cruz Foundation from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia and Frances Paste ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
